Reference : Epidemiology, assessment, and management of excess abdominal fat in persons with HIV inf...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
http://hdl.handle.net/2268/71261
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.
English
Moyle, Graeme [> > > >]
Moutschen, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén. >]
Martinez, Esteban [> > > >]
Domingo, Pere [> > > >]
Guaraldi, Giovanni [> > > >]
Raffi, Francois [> > > >]
Behrens, Georg [> > > >]
Reiss, Peter [> > > >]
2010
AIDS Reviews
12
1
3-14
Yes (verified by ORBi)
International
1139-6121
[en] Anti-Retroviral Agents/therapeutic use ; Exercise Therapy ; Growth Hormone-Releasing Hormone/analogs & derivatives/therapeutic use ; HIV-Associated Lipodystrophy Syndrome/diagnosis/epidemiology/therapy ; Hormones/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use ; Intra-Abdominal Fat/drug effects/pathology ; Metformin/therapeutic use ; Randomized Controlled Trials as Topic ; Risk
[en] Metabolic and morphologic abnormalities in persons with HIV remain common contributors to stigma and morbidity. Increased abdominal circumference and visceral adiposity were first recognized in the late 1990s, soon after the advent of effective combination antiretroviral therapy. Visceral adiposity is commonly associated with metabolic abnormalities including low HDL-cholesterol, raised triglycerides, insulin resistance, and hypertension, a constellation of risk factors for cardiovascular disease and diabetes mellitus known as "the metabolic syndrome". Medline and conference abstracts were searched to identify clinical research on factors associated with visceral adiposity and randomized studies of management approaches. Data were critically reviewed by physicians familiar with the field. A range of host and lifestyle factors as well as antiretroviral drug choice were associated with increased visceral adiposity. Management approaches included treatment switching and metformin, both of which have shown benefit for insulin-resistant individuals with isolated fat accumulation. Testosterone supplements may also have benefits in a subset of individuals. Supra-physiological doses of recombinant human growth hormone and the growth hormone releasing hormone analog tesamorelin both significantly and selectively reduce visceral fat over 12-24 weeks; however, the benefits are only maintained if doping is continued. In summary, the prevention and management of visceral adiposity remains a substantial challenge in clinical practice.
http://hdl.handle.net/2268/71261

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
AIDS_2010_Moyle.pdfPublisher postprint601.36 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.